Trevi Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $146 |
Gross Profit | -38 | -37 | -38 | |
EBITDA | -11,779 | -12,284 | -10,314 | -11,360 |
EBIT | -11,817 | -12,322 | -10,351 | -11,398 |
Net Income | -11,802 | -12,301 | -10,340 | -11,415 |
Net Change In Cash | 0 | 0 | 0 | 146 |
Free Cash Flow | -10,892 | -10,101 | -13,477 | -9,557 |
Cash | 56,869 | 117,058 | 19,374 | 34,097 |
Basic Shares | 145,104 | 130,350 | 117,610 | 106,009 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -147 | -123 | -43 | -50 |
EBITDA | -47,790 | -28,583 | -29,864 | -32,709 |
EBIT | -47,937 | -28,706 | -29,907 | -32,759 |
Net Income | -47,911 | -29,065 | -29,152 | -33,940 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -24,241 | |||
Free Cash Flow | -38,291 | -31,847 | -28,334 | -28,946 |
Cash | 34,097 | 32,397 | 12,589 | 36,830 |
Basic Shares | 101,041 | 99,033 | 64,541 | 22,841 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.08 |
2025-06-30 | -$0.09 |
2025-03-31 | -$0.09 |
